On February 14, 2025, META Pharmaceuticals Inc. announced the completion of tens of millions of yuan in Series A1 financing, led by XtalPi (2228.HK), with participation from IMO Capital, Yayi Capital, and others. The financing will be used to accelerate the advancement of META Pharmaceuticals’ two pipeline drug candidates toward clinical trials, and to further expand the development of its AI-driven metabolic enzyme target discovery platform, achieving innovative target breakthroughs and pipeline asset conversion across more indications.

Currently, META Pharmaceuticals’ two most advanced pipeline drug candidates are an innovative small-molecule targeted therapy for autoimmune diseases and a small-molecule inhibitor for primary hyperoxaluria. Empowered by XtalPi’s AI + robotics R&D platform, the primary hyperoxaluria small-molecule inhibitor has already received Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) from the U.S. FDA, and is expected to complete its Investigational New Drug (IND) application and early-stage clinical trials within the next one to two years.